Risk of venous thromboembolism in users of contraception and menopausal hormone therapy during the COVID-19 pandemic

Pires, Andréa Larissa Ribeiro; Batista, José Gomes; Aldrighi, José Mendes; Massaia, Irineu Francisco Delfino Silva; Delgado, Diego Medeiros; Filho, Edson Santos Ferreira; Soares-Júnior, José Maria

doi:10.1590/1806-9282.66.s2.22

Cited by 11 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, the inflammatory changes are part of coronavirus disease 2019 (COVID-19) pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. The thrombosis risk of ET patients affected by COVID-19 using combined hormonal therapy should also be evaluated in this respect 24 .…”

Section: Discussionmentioning

confidence: 99%

The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis

Sunu

Güneş

Akat

et al. 2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE:The aim of this study was to compare the incidence of factors associated with an increased risk of thrombosis in patients with essential thrombocythemia.METHODS: A total of 200 patients followed-up in our unit with a diagnosis of essential thrombocythemia in 13 years were analyzed retrospectively.RESULTS: Of the study participants, 60.5% were females and 39.5% were males, with an overall mean (±SD) age of 54.93 (±14.21) years. In 119 patients, Janus Kinase 2 was positive with 56.3% of cases. When two patient categories were defined as those with or without history of thrombosis, no significant differences were found in terms of Janus Kinase 2 positivity, mean age, as well as white blood cells and platelet counts (p>0.05). Also, no significant differences in thrombotic event incidence were found between patient categories defined on the basis of cut-off values for white blood cells (cut-off values of 15×10 3 /mm 3 and 8.7×10 3 /mm 3 ) and platelets (cut-off values of 1500×10 3 /mm 3 ) (p>0.05).CONCLUSION: Although our results are generally in line with the published data, some divergence from previous results has been observed with respect to risk factors for thrombotic events. Absence of a correlation between leukocytosis and thrombosis may be related with the significant decline in white blood cells after treatment. Also, a significant reduction in platelet counts occurring in association with treatment is linked with a lowered incidence of thrombosis. Janus Kinase 2-positive patients had a similar thrombosis frequency with that reported in the literature.

show abstract

Section: Discussionmentioning

confidence: 99%

The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis

Sunu

Güneş

Akat

et al. 2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…In a letter to the Editor sent after the publication of the article, the authors of these recommendations specify that they do not advise against the use of oestrogens, but against the use of oral oestrogens, opening the door to the possibility of using oestrogens transdermally in the case of postmenopausal women in hormonal replacement therapy (HRT) [33]. Similar recommendations have been made by other authors from other countries where COVID-19 has had very high incidence rates, such as Brazil [34]. On the contrary, the Italian Society of Contraception recommends not suspending contraceptive treatment with oestrogens in these types of patients, considering that the suspension of the oestrogen supply could accelerate the progression of COVID-19 [35].…”

Section: Patients With Mild or Asymptomatic Covid-19mentioning

confidence: 90%

Combined hormonal contraception and COVID-19

Lete

2021

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

Aim: This article reviews the possibility of using combined hormonal contraception during the COVID-19 pandemic. Methods: narrative review Results: The factors that protect women from the severity of the disease are analysed, as well as the risk factors for the use of this type of contraception, especially related to the increased risk of a thrombotic event in patients affected by the disease. Finally, the information available on the guidelines for action in patients with COVID-19 using combined hormonal contraception is collected. Conclusions: We can continue to prescribe and use hormonal methods with EE.

show abstract

“…At any rate, we feel that our findings should be taken into consideration when treating women with SHCs in the context of the COVID-19 pandemic. period of time may result in increased risk of developing deep venous thrombosis and pulmonary thromboembolism, this risk being particularly high when various combinations of risk factors come together [4,11].…”

Section: Key Pointsmentioning

confidence: 99%

Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database

Martin

Gil

Navarro-García

et al. 2022

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Background Thromboembolic events (TEs) are known to be a severe complication for COVID-19. They are associated with a systemic inflammatory response syndrome with coagulation cascade activation. Objective The aim of this study was to determine a potential association between the COVID-19 pandemic and the increment of the risk of suspected TEs in women on systemic hormonal contraceptives (SHCs). Patients and MethodsThis study utilised a case/non-case approach in the Spanish Pharmacovigilance Database, which includes more than 290,000 cases of suspected adverse drug reactions (ADRs). The reporting odds ratio (ROR) was calculated during an initial pandemic period in 2020 compared with a pre-pandemic period in 2019 and an additional control period in 2018. Results While there was a decreased number of ADR notifications for any medications and for any type of ADR in patients on SHCs during the pandemic period, the TE ROR for all SHCs was higher in the 2020 pandemic period ] relative to the pre-pandemic period in 2019 [ROR = 6.3 (3.2-12.5)] and the additional control period in 2018 [ROR = 4.6. (2.1-9.9)]. In contrast, ROR for progestogen-only contraceptives was lower during the pandemic as compared with the two control periods. ConclusionThe reported disproportionality of TEs in women on SHCs rose during the pandemic period. This suggests a potential interaction of the drug (SHC) with COVID-19, which led to an increased risk of TEs in women exposed to both factors. This should be taken into consideration in the context of the COVID-19 pandemic.

show abstract

Risk of venous thromboembolism in users of contraception and menopausal hormone therapy during the COVID-19 pandemic

Cited by 11 publications

References 13 publications

The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis

The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis

Combined hormonal contraception and COVID-19

Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database

Contact Info

Product

Resources

About